Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 1/20 | 0.43 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NAPEPLD | Q6IQ20 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21176293 | 0.78 | PTGES (0.45) | PTGESCXCR3MAOAALDH1A1GAA | |
| SCHEMBL19974757 | 0.76 | SMN1; SMN2 (0.42) | PTGESCXCR3MAOASMN1; SMN2ALDH1A1 | |
| SCHEMBL19975256 | 0.76 | CXCR4 (0.46) | ALDH1A1BCHEKMT2AMEN1 | |
| SCHEMBL19975429 | 0.75 | PTGES (0.41) | PTGESCXCR3MAOASMN1; SMN2ALDH1A1 | |
| SCHEMBL19975284 | 0.72 | CYP3A4 (0.45) | SMN1; SMN2ALDH1A1KMT2AKDM4EMEN1 | |
| SCHEMBL21183511 | 0.71 | NAPEPLD (0.39) | PTGESCXCR3MAOANAPEPLD | |
| SCHEMBL19975305 | 0.71 | CXCR3 (0.41) | PTGESCXCR3MAOASMN1; SMN2ALDH1A1 | |
| SCHEMBL19975068 | 0.71 | PTGES (0.43) | PTGESCXCR3MAOASMN1; SMN2ALDH1A1 | |
| SCHEMBL21183555 | 0.70 | PTGES (0.42) | PTGESCXCR3MAOANAPEPLDCYP3A4 | |
| SCHEMBL19975274 | 0.69 | PTGIR (0.41) | ALDH1A1GAABCHEKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220356148-A1 | ANTIVIRAL COMPOUNDS | HAPLOGEN GMBH (AT) | 2022-11-10 | — | — | US | disclosed |
| US-11091428-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-08-17 | — | — | US | disclosed |
| US-11091428-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-08-17 | — | — | US | disclosed |
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | LUNIS CONSULTING GMBH (AT) | 2019-07-25 | — | — | US | disclosed |
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | LUNIS CONSULTING GMBH (AT) | 2019-07-25 | — | — | US | disclosed |
| EP-3512836-A1 | ANTIVIRAL COMPOUNDS | Haplogen GmbH (AT) | 2019-07-24 | — | — | EP | disclosed |
| WO-2018050631-A1 | ANTIVIRAL COMPOUNDS | HAPLOGEN GMBH (AT) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | PLA2G1B, PLA2G12A, PLA2G4C | PTGES 138/4885CXCR3 430/4885MAOA 1107/4885 |
| US-20220356148-A1 | ANTIVIRAL COMPOUNDS | PLA2G12A, PLA2G1B, PLA2G4C | PTGES 149/4885CXCR3 637/4885MAOA 990/4885 |
| US-11091428-B2 | Antiviral compounds | PLA2G1B, PLA2G12A, PLA2G4C | PTGES 138/4885CXCR3 430/4885MAOA 1107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.